| Obesity, diabetes mellitus, and liver fibrosis. | |
| | |
MedLine Citation:
|
PMID: 21350183 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Obesity is a global epidemic with more than 1 billion overweight adults and at least 300 million obese patients worldwide. Diabetes is characterized by a defect in insulin secretion or a decrease in sensitivity to insulin, which results in elevated fasting blood glucose. Both obesity and elevated fasting glucose are risk factors for nonalcoholic fatty liver disease, a disease spectrum that includes hepatic steatosis (nonalcoholic fatty liver), nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. Increased adiposity and insulin resistance contribute to the progression from NASH to fibrosis through the development of a profibrotic mileau in the liver, including increased hepatocellular death, increased reactive oxygen species generation, and an altered adipokine/cytokine balance. This review will summarize recent advances in our understanding of the pathological interactions among excessive fat accumulation, insulin resistance, and hepatic fibrogenesis and discuss specific molecular pathways that may be of interest in the development of therapeutic interventions to prevent and/or reverse hepatic fibrosis. |
| | |
Authors:
|
Dian J Chiang; Michele T Pritchard; Laura E Nagy |
Related Documents
:
|
16290993 - Alterations of high-density lipoprotein subclasses in endogenous hypertriglyceridemia. 8614923 - Cigarette smoking is correlated with the periventricular hyperintensity grade of brain ... 11251683 - Reducing hospital inpatient length of stay for patients with diabetes. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review Date: 2011-02-24 |
Journal Detail:
|
Title: American journal of physiology. Gastrointestinal and liver physiology Volume: 300 ISSN: 1522-1547 ISO Abbreviation: Am. J. Physiol. Gastrointest. Liver Physiol. Publication Date: 2011 May |
Date Detail:
|
Created Date: 2011-04-28 Completed Date: 2011-06-28 Revised Date: 2012-05-01 |
Medline Journal Info:
|
Nlm Unique ID: 100901227 Medline TA: Am J Physiol Gastrointest Liver Physiol Country: United States |
Other Details:
|
Languages: eng Pagination: G697-702 Citation Subset: IM |
Affiliation:
|
Dept. of Gastroenterology and Hepatology, Cleveland Clinic, OH 44195, USA. chiangd@ccf.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenosine A2 Receptor Antagonists
/
therapeutic use Animals Diabetes Complications / pathology* Diabetes Mellitus / pathology* Extracellular Matrix / pathology Fatty Liver / complications, pathology Humans Liver Cirrhosis / complications*, pathology Obesity / complications*, pathology Reactive Oxygen Species / metabolism |
| Grant Support | |
ID/Acronym/Agency:
|
AA-017918/AA/NIAAA NIH HHS; R01AA-11876/AA/NIAAA NIH HHS; R01AA-11975/AA/NIAAA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Adenosine A2 Receptor Antagonists; 0/Reactive Oxygen Species |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Temper, Temperature, and Temptation: Heat-Related Retaliation in Baseball.
Next Document: Chronic ethanol feeding causes depression of mitochondrial elongation factor Tu in the rat liver: im...